New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
08:35 EDTBMRNBioMarin should be bought on any weakness, says RW Baird
Baird recommends taking advantage of any weakness in BioMarin following its positive announcement the BMN-701 met the criteria to advance to Phase ll/lll. The firm believes the announcement was tempered by the proposed path to registration and clinical endpoints but could still be meaningfully differentiated from its existing competitor. Shares are Outperform rated with a $63 price target.
News For BMRN From The Last 14 Days
Check below for free stories on BMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:02 EDTBMRNCatalyst Pharmaceutical, BioMarin in amended license agreement
Catalyst Pharmaceutical (CPRX) disclosed in a regulatory filing that on April 15, effective as of April 8, the company and BioMarin Pharmaceutical (BMRN) entered into Amendment No. 1 to License Agreement, amending in certain respects the License Agreement, dated October 26, 2012, between the company and BioMarin. The company intends to submit a FOIA Confidential Treatment Request to the SEC pursuant to Rule 24b-2 under the SEC Act of 1934, as amended, requesting that it be permitted to redact certain portions of the Amendment. The omitted material will be included in the request for confidential treatment.
April 14, 2014
08:22 EDTBMRNBioMarin says FDA extends Kuvan market exclusivity by six months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use